| Autor: |
Miakova NV; Research Institute of Pediatric Hematology and Oncology, Ministry of Health of the RF, Russian Children's Clinical Hospital, Moscow., Aleĭnikova OV, Hartmann R, Rudneva AE, Trubina NM, Fechina LG, Timakov AM, Shamardina AV, Lebedev VV, Varfolomeeva SIu, Dudkin SD, Dyshlevaia ZM, Timofeeva VN, Rumiantsev AG, Henze H, Karachunskiĭ AI |
| Jazyk: |
ruština |
| Zdroj: |
Voprosy onkologii [Vopr Onkol] 2002; Vol. 48 (3), pp. 347-51. |
| Abstrakt: |
Prognosis for children treated according to the BFM-90m protocol (Berlin-Frankfurt-Munster Group) for acute lymphoblastic leukemia (ALL) improved significantly as compared with previous modalities. Methotrexate was used in the dose of 1,000 mg/m2, 36 h. The paper presents the 10-year results for this modification. Patients aged 0-15 years were treated at hematological hospitals of Moscow, other Russian towns and in Minsk, Belarus, (July 5, 1990-November 11, 2000). BFM-90m treatment was given to 682 children out of 1,326 with primary diagnosis of ALL; a comparative trial of the MB-91 protocol hed been carried out at the same clinics since 1991. During 10 years, recurrence-free survival was 72% while overall survival--77%. Toxicity of side-effects was tolerable. The BFM-90m treatment showed significantly better results in both countries. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
